This information is based on a systematic review of scientific literature, and was peer-reviewed and edited by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Brent Bauer, MD (Mayo Clinic); Ashley Brigham, PharmD (Northeastern University); J. Kathryn Bryan, BA (Natural Standard Research Collaboration); Nicole Giese, MS (Natural Standard Research Collaboration); Juliann Goodfriend, PharmD (Northeastern University); Thuy-Duong Le, PharmD (Oregon State University); Jason Mahoney, BA (Natural Standard Research Collaboration); Audrey Nealon, PharmD (Northeastern University); Todd Porter, PhD (University of Kentucky); Rebecca Strauss, PharmD (Northeastern University); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Kenneth Triptow, PharmD (Drake University); Wendy Weissner, BA (Natural Standard Research Collaboration).
Ambrosio LA, Marchese G, Filippo A, et al. The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation. J Int Med Res 1993;21(3):138-146.
Arosio E, Ferrari G, Santoro L, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg 2001;22(4):365-372.
Bettini R, Maino C, Gorini M. [Effectiveness of mesoglycan in the prevention of cerebral ischemia]. Clin Ter 2003;154(1):13-16.
Blardi P, Messa G, Puccetti L, et al. [Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man]. Recenti Prog.Med. 1995;86(7-8):282-289.
Giorgetti PL, Marenghi MC, Bianciardi P. [Heparan sulfate in the therapy of postphlebitic syndrome. Evaluation of the efficacy and tolerability as compared to mesoglycan]. Minerva Cardioangiol. 1997;45(6):279-284.
Kobayashi T, Osakabe T, Seyama Y. Comparison of elastolytic activity between experimental aneurysm and experimental diabetes mellitus. Biol Pharm Bull. 1998;21(7):775-777.
La Marca G, Pumilia G, Martino A. [Effectiveness of mesoglycan topical treatment of leg ulcers in subjects with chronic venous insufficiency]. Minerva Cardioangiol. 1999;47(9):315-319.
Laurora G, Ambrosoli L, Cesarone MR, et al. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study. Panminerva Med. 1994;36(2):83-86.
Maehira F, Zaha F, Miyagi I, et al. Effects of passive smoking on the regulation of rat aortic cholesteryl ester hydrolases by signal transduction. Lipids 2000;35(5):503-511.
Messa G, Blardi P, La Placa G, et al. [Effects of 2 single oral doses of mesoglycan on the coagulation-fibrinolysis system in man. A pharmacodynamic study]. Recenti Prog.Med. 1995;86(7-8):272-281.
Nenci GG, Gresele P, Ferrari G, et al. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb.Haemost. 2001;86(5):1181-1187.
Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol. 1997;45(7-8):383-392.
Scondotto G, Catena G, Aloisi D. [Use of mesoglycan in venous pathology]. Minerva Med. 1997;88(12):537-541.
Tardieu M, Bourin MC, Desgranges P, et al. Mesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs). Growth Factors 1994;11(4):291-300.
Tovar AM, Cesar DC, Leta GC, et al. Age-related changes in populations of aortic glycosaminoglycans: species with low affinity for plasma low-density lipoproteins, and not species with high affinity, are preferentially affected. Arterioscler.Thromb.Vasc.Biol. 1998;18(4):604-614.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.